Last updated on May 2018

A Study to Investigate BAY2402234 a Dihydroorotate Dehydrogenase (DHODH) Inhibitor in Myeloid Malignancies

Brief description of study

To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, or pharmacological active dose of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Clinical Study Identifier: NCT03404726

Find a site near you

Start Over